Indacaterol + Mometasone
Availability of ACE Drug Guidance
Yes
Biologics Drug Information Overview
No
Subsidy Information and Financing Scheme
No
Active ingredients: Indacaterol | Mometasone
General information
Subsidy Information and Financing Scheme
Not Applicable
Drug Guidance for Subsidy
[R] The Ministry of Health’s Drug Advisory Committee has recommended the following inhaled corticosteroid/long-acting beta2 agonist (ICS/LABA) inhalers for inclusion on the MOH Standard Drug List (SDL) for treating asthma in view of acceptable clinical and cost-effectiveness:
Fluticasone furoate/vilanterol (Relvar Ellipta) 100/25 mcg (30 inhalations) and 200/25 mcg (30 inhalations) inhalation powder;
Budesonide/formoterol (DuoResp Spiromax) 160/4.5 mcg (120 inhalations) and 320/9 mcg (60 inhalations) inhalation powder.
[R] The Committee has also recommended the following ICS/LABA inhalers for retention on the MOH SDL, in view of acceptable proposals from the companies:
Fluticasone propionate/salmeterol (Seretide Accuhaler) 100/50 mcg (60 inhalations), 250/50 mcg (60 inhalations), 500/50 mcg (60 inhalations) inhalation powder;
Fluticasone propionate/salmeterol (Seretide Evohaler) 50/25 mcg (120 inhalations), 125/25 mcg (120 inhalations), 250/25 mcg (120 inhalations) inhalation aerosol;
Budesonide/formoterol (Symbicort Turbuhaler) 160/4.5 mcg (120 inhalations) inhalation powder;
Budesonide/formoterol (Symbicort Rapihaler) 80/2.25 mcg (120 inhalations), 160/4.5 mcg (120 inhalations) inhalation aerosol.
[NR] Of note, Symbicort Turbuhaler 80/4.5 mcg, 320/9 mcg and Symbicort Rapihaler 80/4.5 mcg will be delisted with effect from 1 August 2023 due to discontinuation by the company.
The subsidy class and subsidy implementation dates (if applicable) for all ICS/LABA inhalers are provided in the Annex.
Registered Product(s) Information
Clinical and product info
Clinical info | Product Info |
|---|---|
Information under the Indication, Dosage and Contraindication sections are extracted from the relevant Package Insert/Patient Information Leaflet of the product available on HSA Infosearch. For more information, please refer to the product's Package Insert/ Patient Information Leaflet available on HSA Infosearch (opens in new tab). The information provided is for informational purposes only, and is not exhaustive. The information provided is not a substitute for professional medical advice. Please consult a qualified healthcare provider for any medical advice. | Information available here are product details as registered with the HSA. As this website is updated monthly, please refer to HSA Infosearch (opens in new tab) for the most updated product information. |
Respiratory (inhalation)
ATECTURA BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /160 MCG [SIN16148P]*
ATECTURA BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /320 MCG [SIN16147P]*
ATECTURA BREEZHALER INHALATION POWDER, HARD CAPSULE 150 MCG /80 MCG [SIN16149P]*
* Clinical information is available for this product.
